Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Investor Relations

Welcome to Trovagene Investor Relations

Corporate Profile

Trovagene is a clinical-stage, oncology therapeutics company, taking a precision medicine approach and integrating a biomarker strategy to develop targeted drugs to treat leukemias, lymphomas and solid tumor cancers. Our drug candidate, onvansertib, is a first-in-class, 3rd generation Polo-like Kinase Inhibitor with best-in-class attributes. Onvansertib is highly-selective for PLK1, which is over-expressed in most cancers; it is orally administered; synergistic in combination with numerous chemotherapies and targeted therapeutics; has a half-life of 24-hours which allows for flexibility in dosing and schedule. We are developing onvansertib as part of combination regimens with already approved drugs for the treatment of cancers and indications where there is a significant medical need for new treatment options.

Video Overview
Company Overview Download
Recent News
Feb 19, 2019

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor...

Feb 14, 2019

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of...

Jan 29, 2019

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor...

More >

Stock Information
NASDAQTROV
Contact Investor Relations

Direct     [USA +1] 858-952-7593
E-mail    ir@trovagene.com

Contact

Events
January 29, 2019 - March 29, 2019

Dr. Thomas Adams, CEO and Chairman, and Dr. Mark Erlander, CSO, will present an overview of Trovagene Oncology and provide an update on the clinical development program with Onvansertib....